
BIONANO GENOMICS INC
BNGONASDAQTrading Snapshot
- Day Range
- $1.15 โ $1.19
- 52-Week Range
- $1.00 โ $5.50
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 11.5M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $29M
- Last Q Revenue
- $8M
- P/E Ratio
- โ
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-5.11
- Dividend Yield
- โ
Why Investors Own BNGO
- โHigh-growth profile โ revenue up +47.1% YoY with expanding US Equity exposure.
- โHealthy economics โ 61% gross margin and 11% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIONANO GENOMICS INC
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Bionano Genomics, Inc.

Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsAlbert Luderer - Chairman, Interim CEO, Interim President...
Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est
Bionano Genomics (NASDAQ:BNGO) raises FY2026 sales outlook from $30.000 million-$33.000 million to $31.000 million-$33.000 million vs $32.137 million estimate.
Bionano Genomics Sees Q3 Sales $8.200M-$8.600M vs $8.575M Est
Bionano Genomics (NASDAQ:BNGO) sees Q3 sales of $8.200 million-$8.600 million vs $8.575 million analyst estimate.